Open AccessCONTEMPORARY TREATMENT OF ALK POSITIVE NON SMALL CELL LUNG CANCER PATIENT WITH BRAIN METASTASES: OUR EXPERIENCE
Author(s) -
Simonida Crvenkova,
Marija Popova
Publication year - 2020
Publication title -
international journal of medical and biomedical studies
Language(s) - English
Resource type - Journals
eISSN - 2589-8698
pISSN - 2589-868X
DOI - 10.32553/ijmbs.v4i1.835
Subject(s) - alectinib , medicine , anaplastic lymphoma kinase , lung cancer , discontinuation , brain metastasis , oncology , adverse effect , cancer , metastasis , malignant pleural effusion
Purpose: The aim of this study is to show alectinib efficacy and safety, with focus on alectinib intracranial efficacy.
Case presentation: We report on a 46-year-old woman diagnosed as non small cell lung cancer harboring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. She has intracranial metastases and poor performance status of 3. We treated this patients with alectinib after whole brain irradiation and discontinuation of chemotherapy after two 2 cycles due to progressive brain and liver metastases. Good response was obtained with improving of her performance status without adverse events.
Conclusions: We recommend alectinib as a treatment approach for ALK+ NSCLC patients, especially those with CNS metastases at the time of the diagnosis and poor PS.
Key words: CNS metastasis, ALK+ NSCLC patients, alectinib